Kyprolis carfilzomib regulatory update

Onyx partnered with Idis Ltd. (Weybridge, U.K.) to launch a managed access program to provide patients in certain European countries access to carfilzomib to treat patients with multiple myeloma (MM) who received >=2 prior lines of therapy, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy. Onyx said it plans to submit an MAA to EMA in 2H14. ...